Vanda Pharmaceuticals Inc. held its annual meeting of stockholders on June 5, 2025. During the meeting, several proposals were presented. The election of Stephen Ray Mitchell, M.D., and Tage Honoré, Ph.D., D.Sc., as Class I directors was approved. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. An amendment to the company's Amended and Restated 2016 Equity Incentive Plan, which included an increase in the aggregate number of shares authorized for issuance and the elimination of its term, was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.